Synthetic ligament technology has undergone a substantial transformation over the past five decades. Early devices such as Dacron, carbon fiber, Gore-Tex, Kennedy LAD, and Leeds-Keio were developed as full ligament substitutes and initially offered attractive mechanical strength and the possibility of avoiding donor-site morbidity. However, long-term follow-up consistently revealed high rupture rates, synovitis, foreign-body reactions, and progressive degenerative joint changes that ultimately led to their abandonment. More recent systems including LARS demonstrated improved short- and mid-term performance, yet concerns persist regarding biological integration, mechanical wear, and long-term durability. In parallel with these historical limitations, contemporary approaches have shifted from replacement toward biologically oriented augmentation. High-strength suture-tape constructs such as the InternalBrace™ and dynamic stabilization systems such as DIS now function as load-sharing devices that protect healing tissue rather than act as permanent intra-articular grafts. These strategies have shown encouraging early outcomes, lower inflammatory risks and the potential for accelerated rehabilitation across cruciate and extra-articular ligament applications. Despite these advances, synthetic materials cannot currently replicate the long-term behavior of autografts, which remain the standard for ligament reconstruction. Synthetic augmentation may be valuable in selected cases, such as multiligament injuries, limited graft availability, or situations requiring early functional recovery. Long-term prospective studies, registry-level surveillance, and comparative cost-effectiveness analyses are still needed to clarify the precise role of synthetic technologies in modern ligament surgery.